Clinical trials: Cancer: Solid Tumors
Advanced Solid Tumors
Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors
This is a safety, pharmacokinetic and pharmacodynamic study designed to estimate the maximum tolerated dose (MTD), and determine the Recommended Phase 2 Dose (RP2D) of SYHA1801, a BRD4 inhibitor in patients with advanced solid…
- Trial name
- NCT04309968
- Testing
- Drug: SYHA1801
- Where
- China
- Volunteers
- 186 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00388089
- Testing
- bortezomib, topotecan hydrochloride, flow cytometry
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, Davis
PTCH1 or SMO Activated Solid and Hematologic Tumors
LDE225 for Patients With PTCH1 or SMO Mutated Tumors
The purpose of this signal seeking study is to determine whether treatment with LDE225 demonstrates sufficient efficacy in hedgehog pathway-mutated solid tumors and/or hematologic malignancies to warrant further study
- Trial name
- SIGNATURE (NCT02002689)
- Testing
- LDE225
- Where
- 10 sites in United States
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Refractory Solid Tumors
Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors
Clinical study of oral PI3K/mTOR inhibitor P7170 in patients with advanced refractory solid tumors. The primary objective is to determine the maximum tolerated dose and dose limiting toxicity of oral PI3K/mTOR inhibitor P7170 in…
- Trial name
- NCT01762410
- Testing
- P7170
- Where
- 4 sites in United States, India
- Volunteers
- 60 people
- Sponsor
- Piramal Enterprises Limited
Solid Tumor, Adult, Lymphoma
A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, PK, pharmacodynamics, PGx, and efficacy of fadraciclib administered orally BID.
- Trial name
- NCT04983810
- Testing
- Fadraciclib
- Where
- 4 sites in United States, South Korea and 1 more
- Volunteers
- 330 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
This phase I pilot trial studies the side effects of cluster of differentiation 8 (CD8)+ T cells in treating patients with gastrointestinal tumors that have spread to other places in the body.
- Conditions
- Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma
- Trial name
- NCT02757391
- Testing
- Adoptive Immunotherapy, Aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Small Cell Lung Cancer Extensive Stage, Brain Metastases
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
To characterize feasibility, safety, and/or preliminary efficacy of personalized strategies to adapt standard radiotherapy treatments to individual patient responses.
- Conditions
- Small Cell Lung Cancer Extensive Stage, Brain Metastases, Solid Tumor, Adult, Thoracic Cancer
- Trial name
- PRISM (NCT07139990)
- Testing
- Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort C: Sarcoma Pre-Operative PULSAR
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Texas Southwestern Medical Center
Advanced Malignancy, Advanced Solid Tumors
Safety Study of AMG 228 to Treat Solid Tumors
The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology
- Trial name
- NCT02437916
- Testing
- AMG 228
- Where
- 7 sites in United States, Australia and 3 more
- Volunteers
- 30 people
- Sponsor
- Amgen
Advanced or Metastatic Solid Tumors
A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
The primary purpose of this trial is to assess the tolerability and safety of CHS-1000 alone and in combination with toripalimab-tpzi in participants with advanced solid tumors.
- Trial name
- NCT06389526
- Testing
- CHS-1000, Toripalimab
- Volunteers
- 48 people
- Sponsor
- Coherus Oncology, Inc.
Small Cell Lung Cancer, Soft Tissue Sarcoma
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor designed to improve drug access to deoxyribonucleic acid (DNA) strands, induce DNA damage and counteract its repair in cancer cells.
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer
- Trial name
- EDO-S101 (NCT03345485)
- Testing
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Mundipharma Research Limited
Advanced Solid Tumors, Lymphoma
Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
This is a multi-center, Phase I study of a new investigational drug, VTX-2337, that may stimulate the immune system to help fight cancer.
- Trial name
- NCT00688415
- Testing
- VTX-2337
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Celgene
Cancer, Solid Tumor
Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies
This is an investigator-initiated trial aimed at evaluating the safety and preliminary efficacy of a novel red blood cell-based therapy, where engineered red blood cells are conjugated with checkpoint inhibitors.
- Conditions
- Cancer, Solid Tumor, Hematologic Malignancy
- Trial name
- Reboot-101 (NCT05707325)
- Testing
- engineered red blood cell
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Westlake Therapeutics
Selected Types of Solid Tumor
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors
Brief Summary: The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) alone and in combination with pembrolizumab in…
- Trial name
- NCT07095868
- Testing
- EVM14, Pembrolizumab
- Where
- 7 sites in United States, China
- Volunteers
- 94 people
- Sponsor
- Everest Medicines (Beijing) Co., Ltd.
Solid Tumor
Phase I Study in Advanced Malignancies With 5-ALA
RDT aims to take advantage of the relatively safer toxicity profiles of both lower dose radiation therapy and systemic ALA to treat non-superficial lesions in a manner similar to photodynamic therapy.
- Trial name
- NCT04381806
- Testing
- 5-ALA
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Fox Chase Cancer Center
Tumors
Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours
The purpose of this study is to determine whether doses of 30 mg and 45 mg AZD2171 can be well tolerated without significant drug withdrawal when accompanied by a suitable hypertension management strategy or dose reduction.
- Trial name
- NCT00264004
- Testing
- AZD2171
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 119 people
- Sponsor
- AstraZeneca
Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA.
- Trial name
- NCT06493552
- Testing
- SEphB4-HSA, Pembrolizumab, Gemcitabine
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Vasgene Therapeutics, Inc
Neoplasms
Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED)
The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) when given in combination with intravenous docetaxel in cancer patients with advanced solid…
- Trial name
- NCT00040547
- Testing
- Farnesyl Protein Transferase Inhibitor
- Volunteers
- 29 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, NSCLC
A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors
This study is to evaluate the tolerability and safety of ONO-7428 in participants with unresectable advanced or recurrent solid tumors.
- Trial name
- NCT06816108
- Testing
- ONO-7428
- Where
- 15 sites in Japan
- Volunteers
- 35 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Advanced Solid Tumor
A Study of EOC237 in Patients With Advanced Solid Tumor
This research study is studying an investigational drug called EOC237 in Patients With Advanced Solid Tumor.
- Trial name
- NCT05895825
- Testing
- EOC237
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd
Chronic Myeloproliferative Disorders, Cognitive/Functional Effects
Registry of Older Patients With Cancer
RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.
- Conditions
- Chronic Myeloproliferative Disorders, Cognitive/Functional Effects, Leukemia, Lymphoma
- Trial name
- NCT01137825
- Where
- 7 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.